カルボプラチン
Based on 94 publication(s) in Google Scholar
Carboplatin (NSC 241240) is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin (NSC 241240) is a derivative of CDDP and a potent anti-cancer agent.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.98%
- CAS 番号: 41575-94-4
- 分子式: C6H12N2O4Pt
- 分子量:371.25
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Carboplatin
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Cell. 2025 Dec 11;188(25):7137-7154.e21. [Abstract]
- Mol Cancer. 2024 Jan 10;23(1):12. [Abstract]
- Cancer Discov. 2017 Sep;7(9):984-998. [Abstract]
- Mol Cell. 2025 Apr 3;85(7):1280-1295.e9. [Abstract]
- Cancer Res. 2019 Oct 15;79(20):5233-5244. [Abstract]
- Nat Commun. 2024 Nov 12;15(1):9515. [Abstract]
- J Clin Invest. 2025 Mar 17;135(6):e184283. [Abstract]
- J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]
- J Nanobiotechnology. 2025 Mar 7;23(1):186. [Abstract]
- Genome Med. 2016 Oct 31;8(1):116. [Abstract]
- Research (Wash D C). 2025 Apr 14:29:0177. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- Cell Rep Med. 2023 Aug 15;4(8):101151. [Abstract]
- Cell Rep Med. 2023 Feb 21;4(2):100911. [Abstract]
- Pharmacol Res. 2025 Dec:222:108027. [Abstract]
- Cancer Lett. 2025 Jul 22:632:217944. [Abstract]
- Cancer Lett. 2018 Nov 1:436:75-86. [Abstract]
- Cell Death Dis. 2025 Dec 6. [Abstract]
- Cell Death Dis. 2025 Mar 12;16(1):170. [Abstract]
- Genes Dis. 2025 Aug 9;13(1):101799. [Abstract]
- Dev Cell. 2025 Sep 3:S1534-5807(25)00530-1. [Abstract]
- Acta Pharmacol Sin. 2021 Jan;42(1):108-114. [Abstract]
- Mol Syst Biol. 2023 Jul 11;19(7):e11267. [Abstract]
- J Transl Med. 2024 Feb 21;22(1):192. [Abstract]
- Biomed Pharmacother. 2023 Jul:163:114751. [Abstract]
- Oncogene. 2023 Jul;42(30):2297-2314. [Abstract]
- Oncogene. 2022 Sep;41(37):4271-4281. [Abstract]
- Cell Death Discov. 2026 Jan 9;12(1):11. [Abstract]
- Cell Rep. 2025 Mar 25;44(4):115466. [Abstract]
- Cell Rep. 2023 Mar 20;42(3):112275. [Abstract]
- Br J Cancer. 2026 May 18. [Abstract]
- Elife. 2022 May 3;11:e69255. [Abstract]
- Phytother Res. 2023 Nov;37(11):5315-5327. [Abstract]
- Cell Biosci. 2022 Aug 21;12(1):135. [Abstract]
- Cancer Cell Int. 2024 Dec 27;24(1):433. [Abstract]
- Breast Cancer Res. 2025 Jul 6;27(1):124. [Abstract]
- Cancer Metab. 2025 Mar 17;13(1):14. [Abstract]
- Int J Oncol. 2024 Aug;65(2):77. [Abstract]
- Eng Comput. 2024;40(3):1469-1499. [Abstract]
- Pharmaceuticals (Basel). 2025 Nov 18;18(11):1752. [Abstract]
- ACS Appl Bio Mater. 2024 Dec 16;7(12):7871-7882. [Abstract]
- Cell Rep Methods. 2026 Jun 15;6(6):101339. [Abstract]
- Cancers (Basel). 2026 Mar 31;18(7):1120. [Abstract]
- Cancers (Basel). 2022 Oct 10;14(19):4966. [Abstract]
- ACS Omega. 2026 Jun 23.
- Cancer Sci. 2023 Jul;114(7):2951-2960. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Jul 4;1871(7):167971. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- iScience. 2025 Nov 28;29(1):114293. [Abstract]
- iScience. 2024 Dec 3;27(12):111513. [Abstract]
- iScience. 2022 Sep 6;25(10):105081. [Abstract]
- Gynecol Oncol. 2021 Sep;162(3):788-796. [Abstract]
- Adv Ther. 2024 Jul 18.
- Sci Rep. 2026 May 21. [Abstract]
- Sci Rep. 2019 Aug 12;9(1):11677. [Abstract]
- Cancer Res Treat. 2023 Oct;55(4):1077-1086. [Abstract]
- ACS Pharmacol Transl Sci. 2023 Nov 15;6(12):1884-1897. [Abstract]
- Transl Lung Cancer Res. 2025 Jun 30;14(6):2159-2179. [Abstract]
- Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712. [Abstract]
- J Bone Oncol. 2021 Sep 20:30:100391. [Abstract]
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- Front Oncol. 2024 Jun 27:14:1402851. [Abstract]
- Hum Cell. 2025 Jun 2;38(4):115. [Abstract]
- J Anal At Spectrom. 17 Sep 2021.
- Curr Issues Mol Biol. 2024 Dec 11;46(12):13951-13969. [Abstract]
- Breast Cancer Res Treat. 2021 Sep;189(2):347-361. [Abstract]
- Discov Oncol. 2025 May 19;16(1):814. [Abstract]
- Discov Oncol. 2024 May 11;15(1):154. [Abstract]
- Invest New Drugs. 2024 Aug;42(4):471-477. [Abstract]
- Reprod Sci. 2024 Jul;31(7):1868-1880. [Abstract]
- Exp Ther Med. 2023 Jun 19;26(2):370. [Abstract]
- Biochim Biophys Acta Gen Subj. 2023 Oct;1867(10):130439. [Abstract]
- Laryngoscope. 2020 Dec;130(12):2818-2824. [Abstract]
- Mol Cell Oncol. 2025 Dec 31;13(1):2604899. [Abstract]
- Biochem Genet. 2024 Dec 24. [Abstract]
- Biol Methods Protoc. 2025 Feb 13;10(1):bpaf012. [Abstract]
- Eur J Gynaecol Oncol. 2023 Dec 15.
- bioRxiv. 2026 Apr 7.
- bioRxiv. 2026 Mar 18.
- Res Sq. 2026 Mar 3.
- Res Sq. 2026 Mar 11.
- Res Sq. 2026 Jan 9.
- Res Sq. 2025 Sep 7.
- Res Sq. 2025 Jun 25.
- bioRxiv. 2025 May 24.
- Patent. US20250108213A1.
- Authorea. 2025 Jan 03.
- SSRN. 2024
- bioRxiv. 2024 Jan 7.
- University of Gothenburg. 2023 Jun 27.
- AfricArXiv Preprints. 2212.
- Research Square Print. 2022 Aug.
- Oxid Med Cell Longev. 2022 Mar 29;2022:2371807. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
IHC
-
WB
DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示
More
生物活性
DNA Alkylator[1]
Carboplatin is an antitumor agent, with an increased DNA-binding activity in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts[1].
Carboplatin is less cytotoxic to human ovarian cells such as A2780, SKOV3, IGROV1 and HX62 than 17-AAG, with IC50s of 6.177, 12.442, 2.233 and 116.068 μM, respectively. Moreover, Carboplatin does not affect HSP90 or change the activity of 17-AAG to inhibit HSP90[2].
Carboplatin reduces the viability of Brca1 (IC50, 3.4 μM) and Brca2 cells (IC50, 1.9 μM). Carboplatin (25 μM) combined with ABT-888 also shows an apoptotic effect in BRCA1 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Carboplatin (25 mg/kg, p.o.) combined with ABT-888 delays tumor growth in Brca2 xenografts[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 41575-94-4
-
性状 Solid
-
分子量 371.25
-
分子式 C6H12N2O4Pt
-
Color White to off-white
-
SMILES
O=C1C2(CCC2)C(O[Pt]O1)=O.N.N
-
別名
Carboplatin; NSC 241240
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (94)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Cell
2025 Dec 11;188(25):7137-7154.e21. PMID: 41138726 -
Mol Cancer
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]2024 Jan 10;23(1):12. PMID: 38200517 -
Cancer Discov
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. [Abstract]2017 Sep;7(9):984-998. PMID: 28588062 -
Mol Cell
Transcription-coupled AID deamination damage depends on ELOF1-associated RNA polymerase II. [Abstract]2025 Apr 3;85(7):1280-1295.e9. PMID: 40049162 -
Cancer Res
Phosphorylation of HSF1 by PIM2 Induces PD-L1 Expression and Promotes Tumor Growth in Breast Cancer. [Abstract]2019 Oct 15;79(20):5233-5244. PMID: 31409638 -
Nat Commun
2024 Nov 12;15(1):9515. PMID: 39532854 -
J Clin Invest
High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancer. [Abstract]2025 Mar 17;135(6):e184283. PMID: 40091834 -
J Clin Invest
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models. [Abstract]2024 Mar 7;134(10):e172716. PMID: 38451729
Carboplatin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]
The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM VP-16, 125 nM DXR, 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-FU, 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.
Carboplatin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]
The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.
-
J Nanobiotechnology
Oxygen-delivery nanoparticles enhanced immunotherapy efficacy monitored by granzyme B PET imaging in malignant tumors. [Abstract]2025 Mar 7;23(1):186. PMID: 40050894 -
Genome Med
A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. [Abstract]2016 Oct 31;8(1):116. PMID: 27799065
Carboplatin purchased from MedChemExpress. Usage Cited in: Genome Med. 2016 Oct 31;8(1):116. [Abstract]
Phosphorylation level of RPS6 upon Temsirolimus treatment. The effective target engagement is confirmed in Temsirolimus-treated tumors by showing reduced phosphorylation of downstream mTOR targets, RPS6 and 4EBP1, and an associated increase in autophagy (LC3A/B).
-
Research (Wash D C)
Engineered Endometrial Clear Cell Cancer-on-a-Chip Reveals Early Invasion-Metastasis Cascade of Cancer Cells. [Abstract]2025 Apr 14:29:0177. PMID: 40231208 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
Cell Rep Med
CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells. [Abstract]2023 Aug 15;4(8):101151. PMID: 37567173 -
Cell Rep Med
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]2023 Feb 21;4(2):100911. PMID: 36657446 -
Pharmacol Res
CDC7 stabilized by KRAS signaling reactivation impairs chemosensitivity in KRAS-mutant colorectal cancer. [Abstract]2025 Dec:222:108027. PMID: 41207349 -
Cancer Lett
Dual regulation of FZD1/7 by IGF2BP3 enhances stem-like properties and carboplatin resistance in triple-negative breast cancer. [Abstract]2025 Jul 22:632:217944. PMID: 40706743 -
Cancer Lett
FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer. [Abstract]2018 Nov 1:436:75-86. PMID: 30120964
Carboplatin purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Nov 1:436:75-86. [Abstract]
FTY720+Tamoxifen and FTY720+Carboplatin increase apoptosis marker, cleaved caspase 3 in a PDX model of EOC. IHC of tumor sections is used to detect the apoptosis marker cleaved caspase 3 and the cell cycle inhibitor p21.
-
Cell Death Dis
AQB improves carboplatin sensitivity in endometrial cancer through dual DNA repair modulation: suppression of the p21-E2F1-RAD51 and ATF3-HDAC1-BRCA1 signaling. [Abstract]2025 Dec 6. PMID: 41353219 -
Cell Death Dis
Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]2025 Mar 12;16(1):170. PMID: 40075071 -
Genes Dis
SIGLEC15 modulates the immunosuppressive microenvironment and suppresses malignant phenotypes in triple-negative breast cancer. [Abstract]2025 Aug 9;13(1):101799. PMID: 41158758 -
Dev Cell
A pathological role of O-GlcNAcylation-driven TR11B production and function in lung adenocarcinoma. [Abstract]2025 Sep 3:S1534-5807(25)00530-1. PMID: 40930100 -
Acta Pharmacol Sin
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]2021 Jan;42(1):108-114. PMID: 32398685 -
Mol Syst Biol
A metabolic map of the DNA damage response identifies PRDX1 in the control of nuclear ROS scavenging and aspartate availability. [Abstract]2023 Jul 11;19(7):e11267. PMID: 37259925 -
J Transl Med
ZSWIM4 inhibition improves chemosensitivity in epithelial ovarian cancer cells by suppressing intracellular glycine biosynthesis. [Abstract]2024 Feb 21;22(1):192. PMID: 38383406 -
Biomed Pharmacother
Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. [Abstract]2023 Jul:163:114751. PMID: 37105073 -
Oncogene
GSK3β-driven SOX2 overexpression is a targetable vulnerability in esophageal squamous cell carcinoma. [Abstract]2023 Jul;42(30):2297-2314. PMID: 37349645 -
Oncogene
A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer. [Abstract]2022 Sep;41(37):4271-4281. PMID: 35933519 -
Cell Death Discov
MSLN-mediated activation of EGFR-ERK1/2 signaling drives liver metastasis in breast cancer. [Abstract]2026 Jan 9;12(1):11. PMID: 41513618 -
Cell Rep
Structural basis for the reversal of human MRP4-mediated multidrug resistance by lapatinib. [Abstract]2025 Mar 25;44(4):115466. PMID: 40138312 -
Cell Rep
Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunity. [Abstract]2023 Mar 20;42(3):112275. PMID: 36943864 -
Br J Cancer
Circulating tumour cell-derived xenograft as a preclinical platform for metastatic breast cancer. [Abstract]2026 May 18. PMID: 42151560 -
Elife
2022 May 3;11:e69255. PMID: 35503721 -
Phytother Res
2023 Nov;37(11):5315-5327. PMID: 37469042 -
Cell Biosci
Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer. [Abstract]2022 Aug 21;12(1):135. PMID: 35989326 -
Cancer Cell Int
2024 Dec 27;24(1):433. PMID: 39731167 -
Breast Cancer Res
THEM6 modulates carboplatin sensitivity by regulating ferroptosis through FDFT1 in triple-negative breast cancer. [Abstract]2025 Jul 6;27(1):124. PMID: 40619388 -
Cancer Metab
WTAP contributes to platinum resistance in high-grade serous ovarian cancer by up-regulating malic acid: insights from liquid chromatography and mass spectrometry analysis. [Abstract]2025 Mar 17;13(1):14. PMID: 40098185 -
Int J Oncol
Polydatin, a potential NOX5 agonist, synergistically enhances antitumor activity of cisplatin by stimulating oxidative stress in non‑small cell lung cancer. [Abstract]2024 Aug;65(2):77. PMID: 38873997 -
Eng Comput
A global sensitivity analysis of a mechanistic model of neoadjuvant chemotherapy for triple negative breast cancer constrained by in vitro and in vivo imaging data. [Abstract]2024;40(3):1469-1499. PMID: 39620056 -
Pharmaceuticals (Basel)
YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer. [Abstract]2025 Nov 18;18(11):1752. PMID: 41304997 -
ACS Appl Bio Mater
Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer. [Abstract]2024 Dec 16;7(12):7871-7882. PMID: 38558434 -
Cell Rep Methods
Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC. [Abstract]2026 Jun 15;6(6):101339. PMID: 42134319 -
Cancers (Basel)
Eicosapentaenoic Acid Suppresses Tumor Growth and Enhances Chemosensitivity via AKT/mTOR Signaling in Uterine Serous Carcinoma. [Abstract]2026 Mar 31;18(7):1120. PMID: 41976343 -
Cancers (Basel)
2022 Oct 10;14(19):4966. PMID: 36230889 -
-
Cancer Sci
D-1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity. [Abstract]2023 Jul;114(7):2951-2960. PMID: 37158138 -
Biochim Biophys Acta Mol Basis Dis
Anticancer and chemo-sensitizing effects of annonacin via p53-mediated DNA damage in ovarian cancer. [Abstract]2025 Jul 4;1871(7):167971. PMID: 40618909 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
iScience
Multi-omic integration identifies broad drug resistance mechanisms and strategies to therapeutically reprogram cancer cells. [Abstract]2025 Nov 28;29(1):114293. PMID: 41492468 -
iScience
Zinc finger protein 593 promotes breast cancer development by ensuring DNA damage repair and cell-cycle progression. [Abstract]2024 Dec 3;27(12):111513. PMID: 39758980 -
iScience
Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine. [Abstract]2022 Sep 6;25(10):105081. PMID: 36204272 -
Gynecol Oncol
Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma. [Abstract]2021 Sep;162(3):788-796. PMID: 34183163 -
-
Sci Rep
Effects of adjuvant propofol on antitumoral effects of carboplatin in experimental endometrial cancer: possible epigenetic associations. [Abstract]2026 May 21. PMID: 42168257 -
Sci Rep
Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome. [Abstract]2019 Aug 12;9(1):11677. PMID: 31406154 -
Cancer Res Treat
Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients. [Abstract]2023 Oct;55(4):1077-1086. PMID: 37309112 -
ACS Pharmacol Transl Sci
Novel Combination of Erythropoietin and Romiplostim to Treat Chemotherapy-Induced Anemia and Thrombocytopenia via Pharmacodynamic Interaction on Hematopoietic Stem and Progenitor Cells. [Abstract]2023 Nov 15;6(12):1884-1897. PMID: 38093847 -
Transl Lung Cancer Res
Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer. [Abstract]2025 Jun 30;14(6):2159-2179. PMID: 40673102 -
Transl Lung Cancer Res
Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation. [Abstract]2024 Oct 31;13(10):2698-2712. PMID: 39507032 -
J Bone Oncol
Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. [Abstract]2021 Sep 20:30:100391. PMID: 34611509 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
Front Oncol
Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance. [Abstract]2024 Jun 27:14:1402851. PMID: 38993641 -
Hum Cell
Establishment and comparison of three sublines from a human uterine carcinosarcoma cell line, ESCA. [Abstract]2025 Jun 2;38(4):115. PMID: 40455147 -
-
Curr Issues Mol Biol
Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals CSF3 as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens. [Abstract]2024 Dec 11;46(12):13951-13969. PMID: 39727962 -
Breast Cancer Res Treat
KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer. [Abstract]2021 Sep;189(2):347-361. PMID: 34240274 -
Discov Oncol
2025 May 19;16(1):814. PMID: 40388071 -
Discov Oncol
Preclinical efficacy of CBR-5884 against epithelial ovarian cancer cells by targeting the serine synthesis pathway. [Abstract]2024 May 11;15(1):154. PMID: 38733440 -
Invest New Drugs
177Lu-SN201 nanoparticle shows superior anti-tumor efficacy over conventional cancer drugs in 4T1 orthotopic model. [Abstract]2024 Aug;42(4):471-477. PMID: 38837077 -
Reprod Sci
Hematological and Neurological Expressed 1 Promotes Tumor Progression Through mTOR Signaling in Ovarian Cancer. [Abstract]2024 Jul;31(7):1868-1880. PMID: 38263477 -
Exp Ther Med
Comprehensive analysis of suppressor of cytokine signaling 2 protein in the malignant transformation of NSCLC. [Abstract]2023 Jun 19;26(2):370. PMID: 37415839 -
Biochim Biophys Acta Gen Subj
Poliovirus receptor (PVR) mediates carboplatin-induced PD-L1 expression in non-small-cell lung cancer cells. [Abstract]2023 Oct;1867(10):130439. PMID: 37516256 -
Laryngoscope
2020 Dec;130(12):2818-2824. PMID: 31886905 -
Mol Cell Oncol
SNX1 inhibits human ovarian cancer progression via regulation of the cell cycle, apoptosis and migration. [Abstract]2025 Dec 31;13(1):2604899. PMID: 41487280 -
Biochem Genet
β-Asarone Inhibits Carboplatin Resistance in Retinoblastoma Cells Through the UCA1/miR-206/NRP1 Axis. [Abstract]2024 Dec 24. PMID: 39718722 -
Biol Methods Protoc
Optimizing drug sensitivity assays in patient-derived tumor organoids: a comparison of IC50 estimation methods and experimental parameters. [Abstract]2025 Feb 13;10(1):bpaf012. PMID: 40060949 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Oxid Med Cell Longev
GSDME Increases Chemotherapeutic Drug Sensitivity by Inducing Pyroptosis in Retinoblastoma Cells. [Abstract]2022 Mar 29;2022:2371807. PMID: 35480866
溶剤 & 溶解度
H2O : 8.33 mg/mL (22.44 mM; Need ultrasonic; DMSO can inactivate Carboplatin's activity)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 10 mg/mL (26.94 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
プロトコル
Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying the effect of sequence of exposure to 17-AAG or Carboplatin, cells are exposed to increasing concentrations of 17-AAG or Carboplatin for 24 h. A period of 24-h exposure to the first agent is chosen so that the A2780 cells will be exposed to the first drug for at least one doubling time (18-24 h). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 h) or medium is added for 96 h. SRB assays are carried out. All experiments are carried out in triplicate[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) by injecting 4 × 106 cells in each flank. Mice with established tumors corresponding to a mean volume of 0.69 mm3 are randomized into groups (six animals each) for treatment with either control vehicle (43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water) days 1-4, 17-AAG (80 mg/kg intraperitonially, days 1-4), Carboplatin (60 mg/kg IP day 0) or a combination of 17-AAG (80 mg/kg IP days 1-4) and Carboplatin (60 mg/kg IP day 0). Tumor growth is assessed three times weekly and tumor volumes are calculated according to a validated formula: volume = 4.19 × (a/4 + b/4)3, where a is the longer and b the shorter diameter. Tumor volumes are then expressed as a proportion of the volume at the start of treatment (relative tumor volume)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
純度とドキュメンテーション
-
データシート (284 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Portuguese - PT (419 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Natarajan G, et al. Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem Pharmacol. 1999 Nov 15;58(10):1625-9. [Content Brief]
[2]. Banerji U, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol. 2008 Oct;62(5):769-78. [Content Brief]
[3]. Clark CC, et al. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther. 2012 Sep;11(9):1948-58. [Content Brief]
[4]. Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116. [Content Brief]
[5]. Hall MD, Telma KA, Chang KE, et al. Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. Cancer Res. 2014;74(14):3913-3922. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.6936 mL | 13.4680 mL | 26.9360 mL | 67.3401 mL |
| 5 mM | 0.5387 mL | 2.6936 mL | 5.3872 mL | 13.4680 mL | |
| 10 mM | 0.2694 mL | 1.3468 mL | 2.6936 mL | 6.7340 mL | |
| 15 mM | 0.1796 mL | 0.8979 mL | 1.7957 mL | 4.4893 mL | |
| 20 mM | 0.1347 mL | 0.6734 mL | 1.3468 mL | 3.3670 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz